NuVasive To Participate As Global Partner At 12th Annual Society Of Lateral Access Surgery Meeting

SAN DIEGO May 14, 2019 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company continues its commitment to the Society of Lateral Access Surgery (SOLAS) as a Global Partner, the leading sponsorship level in the partnership program, at the 12th annual SOLAS meeting being held May 16-18, 2019 in Miami, Florida. NuVasive will also participate in exhibit and workshop programs, featuring its comprehensive approach to lateral single-position surgery with the X360™ system integrated with Surgical Intelligence™.

During the meeting, NuVasive will host a lunch symposia, X360 powered by Surgical Intelligence, presented by Brett Braly, MD, and Brian Kwon, MD, on May 17, 2019 from 12:45 to 2:15 p.m. ET. This symposia will discuss the X360 approach, clinical utilization of NuVasive’s Modulus® and Cohere® XLIF® interbody implants and clinical case reviews.

In addition, Dr. Braly will present his paper, “The effect of radiation reduction technology on fluoroscope radiation emission during lumbar interbody fusion for degenerative spinal conditions,” during the scientific sessions highlighting new technologies and techniques on May 17. These preliminary, comparative results suggest the low-dose fluoroscopic images NuVasive’s LessRay image enhancement platform provides are of similar diagnostic capability needed to successfully perform lateral-position interbody fusion and posterior fixation, with nearly 60% reduction in radiation emission.

“NuVasive’s ongoing partnership and support of SOLAS is representative of our deep commitment to advancing the latest knowledge and technological advancements within lateral access surgery,” said Matt Link, president of NuVasive. “As the only SOLAS Global Partner, NuVasive continues to lead lateral spine surgery with enabling technologies, surgeon education and clinical research to help surgeons deliver more reproducible clinical outcomes in spine surgery.”

SOLAS and NuVasive align in their missions to advance minimally invasive surgery (MIS) in spine. MIS is the fastest growing sub-market in spine, driven by innovation from NuVasive that continues to push the boundaries of lateral surgery. Sixteen years ago, NuVasive revolutionized spine surgery with XLIF, the only lateral approach spine procedure supported by extensive clinical evidence in more than 400 peer-reviewed publications. Now, with the recent introduction of the X360 system, NuVasive has delivered the most comprehensive approach to lateral single-position surgery, leveraging advanced techniques and technologies to deliver best-in-class care, while enhancing operating room workflow and efficiency.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


Media Contact:
Michelle Stansbury
(619) 663-9704
[email protected]


Investor Contact:
Suzanne Hatcher
NuVasive, Inc.
[email protected]

Previous PostNext Post